151 related articles for article (PubMed ID: 34385507)
1. Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid.
Gama RR; Arantes LMRB; Sorroche BP; De Marchi P; Melendez ME; Carvalho RS; de Lima MA; Vettore AL; Carvalho AL
Sci Rep; 2021 Aug; 11(1):16415. PubMed ID: 34385507
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A
Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612
[TBL] [Abstract][Full Text] [Related]
4. Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.
Rozek LS; Virani S; Bellile EL; Taylor JMG; Sartor MA; Zarins KR; Virani A; Cote C; Worden FP; Mark MEP; McLean SA; Duffy SA; Yoo GH; Saba NF; Shin DM; Kucuk O; Wolf GT
Nutr Cancer; 2019; 71(5):772-780. PubMed ID: 30862188
[TBL] [Abstract][Full Text] [Related]
5. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Chavez-Blanco A; Segura-Pacheco B; Perez-Cardenas E; Taja-Chayeb L; Cetina L; Candelaria M; Cantu D; Gonzalez-Fierro A; Garcia-Lopez P; Zambrano P; Perez-Plasencia C; Cabrera G; Trejo-Becerril C; Angeles E; Duenas-Gonzalez A
Mol Cancer; 2005 Jul; 4(1):22. PubMed ID: 16001982
[TBL] [Abstract][Full Text] [Related]
6. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma.
Longo AL; Rettori MM; de Carvalho AC; Kowalski LP; Carvalho AL; Vettore AL
Head Neck; 2014 May; 36(5):631-7. PubMed ID: 23595968
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive epigenetic analysis using oral rinse samples: a pilot study.
Kusumoto T; Hamada T; Yamada N; Nagata S; Kanmura Y; Houjou I; Kamikawa Y; Yonezawa S; Sugihara K
J Oral Maxillofac Surg; 2012 Jun; 70(6):1486-94. PubMed ID: 21821326
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital PCR of tumor suppressor gene methylation in serial oral rinses of patients with head and neck squamous cell carcinoma.
Fung SYH; Chan KCA; Wong EWY; Ng CWK; Cho R; Yeung ZWC; Lam JWK; Chan JYK
Head Neck; 2021 Jun; 43(6):1812-1822. PubMed ID: 33594807
[TBL] [Abstract][Full Text] [Related]
12. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Haddad R; Guigay J; Keilholz U; Clement PM; Fayette J; de Souza Viana L; Rolland F; Cupissol D; Geoffrois L; Kornek G; Licitra L; Melichar B; Ribaldo Nicolau U; Rauch D; Zanetta-Devauges S; Cohen EEW; Machiels JP; Tahara M; Vermorken J; Geng Y; Zografos E; Gauler T
Oral Oncol; 2019 Oct; 97():82-91. PubMed ID: 31450171
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylome Distinguishes Head and Neck Cancer from Potentially Malignant Oral Lesions and Healthy Oral Mucosa.
Milutin Gašperov N; Sabol I; Božinović K; Dediol E; Mravak-Stipetić M; Licastro D; Dal Monego S; Grce M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961999
[TBL] [Abstract][Full Text] [Related]
15. Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation.
Ziyatdinova S; Viswanathan J; Hiltunen M; Tanila H; Pitkänen A
Epilepsy Res; 2015 May; 112():43-55. PubMed ID: 25847338
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
Bauman JE; Duvvuri U; Gooding WE; Rath TJ; Gross ND; Song J; Jimeno A; Yarbrough WG; Johnson FM; Wang L; Chiosea S; Sen M; Kass J; Johnson JT; Ferris RL; Kim S; Hirsch FR; Ellison K; Flaherty JT; Mills GB; Grandis JR
JCI Insight; 2017 Mar; 2(6):e90449. PubMed ID: 28352657
[No Abstract] [Full Text] [Related]
18. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
19. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
De Schutter H; Kimpe M; Isebaert S; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
[TBL] [Abstract][Full Text] [Related]
20. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation.
Tabolacci E; De Pascalis I; Accadia M; Terracciano A; Moscato U; Chiurazzi P; Neri G
Pharmacogenet Genomics; 2008 Aug; 18(8):738-41. PubMed ID: 18622267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
